Triptorelin ( DrugBank: Triptorelin )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
49	全身性エリテマトーデス	1
76	下垂体性ゴナドトロピン分泌亢進症	5

49. 全身性エリテマトーデス

臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00124514 (ClinicalTrials.gov)	June 2003	26/7/2005	Triptorelin for Ovary Protection in Childhood Onset Lupus		Systemic Lupus Erythematosus	Drug: Triptorelin pamoate	Children's Hospital Medical Center, Cincinnati	Watson Pharmaceuticals	Completed	9 Years	21 Years	Female	30	Phase 2	United States;Brazil

76. 下垂体性ゴナドトロピン分泌亢進症

臨床試験数 : 29 / 薬物数 : 44 - (DrugBank : 14) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 15

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05029622 (ClinicalTrials.gov)	August 10, 2021	9/8/2021	A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.	A Phase III, Open-label, Multicentre, Single Arm Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Chinese Paediatric Participants With Central Precocious Puberty.	Central Precocious Puberty	Drug: Triptorelin Pamoate	Ipsen	NULL	Completed	N/A	10 Years	All	66	Phase 3	China
2	NCT04736602 (ClinicalTrials.gov)	March 27, 2021	29/1/2021	Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty.	An Open-label, Multicentre, Single Arm Study to Assess the Efficacy and Safety of Triptorelin 3-month Formulation in Chinese Children With Central Precocious Puberty	Central Precocious Puberty	Drug: Triptorelin pamoate 15mg	Ipsen	NULL	Completed	N/A	10 Years	All	32	Phase 3	China
3	NCT01467882 (ClinicalTrials.gov)	April 2012	7/11/2011	Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty	An Open-label, Non-comparative, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Triptorelin Pamoate (Embonate) 22.5 mg 6-month Formulation in Patients Suffering From Central (Gonadotropin-dependent) Precocious Puberty	Central Precocious Puberty	Drug: Triptorelin	Debiopharm International SA	NULL	Completed	2 Years	9 Years	All	44	Phase 3	United States;Chile;Mexico
4	NCT00438217 (ClinicalTrials.gov)	May 2006	21/2/2007	Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children	Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children	Central Precocious Puberty	Drug: Triptorelin (GnRH agonists);Drug: Leuprolide (GnRH agonists)	University of Pisa	NULL	Recruiting	1 Year	18 Years	Both	100	Phase 4	Italy
5	EUCTR2015-001607-30-Outside-EU/EEA (EUCTR)		24/04/2015	Triptorelin 6-month formulation for children who mature too early because of a brain hormone	An open-label, non-comparative, multicenter study on the efficacy, safety, and pharmacokinetics of triptorelin pamoate (embonate) 22.5 mg 6-month formulation in patients suffering from central (gonadotropin-dependent) precocious puberty - Triptorelin 6-month Formulation in Patients With Central Precocious Puberty	Central Precocious Puberty MedDRA version: 18.0;Level: PT;Classification code 10058084;Term: Precocious puberty;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Body processes [G] - Biological Phenomena [G16]	INN or Proposed INN: TRIPTORELIN Other descriptive name: Triptorelin embonate, Triptorelin pamoate	Debiopharm International, S.A.	NULL	NA			Female: yes Male: yes	44		United States;Chile;Mexico